Scientists at NDSU have developed a monoclonal antibody that inhibits activation of the receptor for advanced glycation end products (RAGE) by blocking the V-domain.

About

Invention Summary: Scientists at NDSU have developed a monoclonal antibody that inhibits activation of the receptor for advanced glycation end products (RAGE) by blocking the V-domain. The V-domain binds multiple ligands that elicit sustained inflammation associated with diabetes, cancer, Alzheimer’s, multiple sclerosis, and other diseases. As a result, this monoclonal has value in research related to a wide variety of diseases. This antibody is available via non-exclusive license for research use only.  Illustration and antibody specification figures are shown below. Patents: PCT/US2015/047478 was filed August 28, 2015, and will publish on February 28, 2016.  The antibody has been non-exclusively licensed to multiple licensees for research purposes.  

Register for free for full unlimited access to all innovation profiles on LEO

  • Discover articles from some of the world’s brightest minds, or share your thoughts and add one yourself
  • Connect with like-minded individuals and forge valuable relationships and collaboration partners
  • Innovate together, promote your expertise, or showcase your innovations